“With enrollment completed in our silevertinib Phase 2 trial for the treatment of newly diagnosed patients with EGFRm NSCLC, we look forward to sharing a clinical update in the fourth quarter of 2025,” said Mark Velleca, M.D., Ph.D., President and Chief Executive Officer of Black Diamond Therapeutics (BDTX). “Given the evolving competitive and regulatory landscape, we are also exploring partnership opportunities to advance silevertinib into pivotal development and bring this potential best-in-class treatment to patients as quickly as possible.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDTX:
- Black Diamond, Nike, Apple, Block, IonQ: Trending by Analysts
- Optimistic Buy Rating for Black Diamond Therapeutics: Promising BDTX-1535 Drug and Strong Financial Position
- Black Diamond Therapeutics resumed with an Outperform at Raymond James
- Black Diamond’s 2025 Annual Stockholders Meeting Highlights